Evidence map›Paper›PMID 29541976›Full record

ArticleBreast cancer research and treatment2018

A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing.

Kelly Kyker-Snowman, Bracha Erlanger Avigdor, Mansoor Nasim, Ashley Cimino-Mathews, Sarah J Wheelan, Pedram Argani, Ben Ho Park

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kelly Kyker-SnowmanDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Bracha Erlanger AvigdorDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mansoor NasimDepartment of Anatomic Pathology, Northwell Pathology, Northshore University Hospital Long Island Jewish Medical Center, Cohen Children Hospital, Lake Success, NY, 11040, USA.
Ashley Cimino-MathewsDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sarah J WheelanDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. swheelan@jhmi.edu.
Pedram ArganiDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. pargani@jhmi.edu.
Ben Ho ParkDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. bpark2@jhmi.edu.ORCID http://orcid.org/0000-0001-8119-2291

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Circulating plasma tumor DNA as a biomarker for early stage breast cancerR01CA194024 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO · 2016 to 2020
$1.9M
Molecular complete response in blood as a predictor for pathologic complete response after neoadjuvant therapy for breast cancerR01CA214494 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO · 2018 to 2023
$1.1M
NCI NIH HHS P30 CA006973NCI NIH HHS P30CA006973NCI NIH HHS R01 CA194024NCI NIH HHS R01CA194024NCI NIH HHS R01 CA214494
6 · The paper itself

Abstract

background/purposeTumor heterogeneity is a now well-recognized phenomenon that can affect the classification, prognosis and treatment of human cancers. Heterogeneity is often described in primary breast cancers based upon histologic subtypes, hormone- and HER2-receptor status, and immunolabeling for various markers, which can be seen within a single tumor as mixed cellular populations, or as separate discrete foci. EXPERIMENTAL DESIGN/

methodsHere, we present a case report of a patient's primary breast cancer that had two separate but adjacent histologic components, one that was estrogen receptor (ER) positive, and the other ER negative. Each component was subjected to whole exome sequencing and compared for gene identity to determine clonal origin.

resultsUsing prior bioinformatic tools, we demonstrated that both the ER positive and negative components shared many variants, including passenger and driver alterations. Copy number variations also supported the two components were derived from a single common clone.

conclusionsThese analyses strongly suggest that the two ER components of this patient's breast cancer were derived from the same clonal origin. Our results have implications for the evolution of breast cancers with mixed histologies, and how they might be best managed for optimal therapy.

Indexed as

Exome SequencingQuantitative Trait LociAdultBiomarkers, TumorBreast NeoplasmsClonal EvolutionComputational BiologyDNA Copy Number VariationsEstrogen Receptor alphaFemaleHumansImmunohistochemistryBiomarkers, TumorEstrogen Receptor alphaBreast cancerEstrogen receptorWhole exome sequencing

Identifiers

PMID29541976
PMCPMC6002904

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.